Skip to Content

Juvisync Approval History

FDA Approved: Yes (Discontinued) (First approved October 7, 2011)
Brand name: Juvisync
Generic name: simvastatin and sitagliptin
Dosage form: Tablets
Company: Merck
Treatment for: Diabetes, Type 2, High Cholesterol, Familial Homozygous, High Cholesterol, Familial Heterozygous, Hypertriglyceridemia

Marketing Status: Discontinued

Juvisync (simvastatin and sitagliptin) is an HMG-CoA reductase inhibitor (statin) and dipeptidyl peptidase-4 (DPP-4) inhibitor fixed dose combination for the treatment of high cholesterol and type 2 diabetes.

Development History and FDA Approval Process for Juvisync

DateArticle
Oct  7, 2011Approval FDA Approves Combination Therapy Juvisync

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide